Health Care & Life Sciences » Pharmaceuticals | Nicoccino Holding AB

Nicoccino Holding AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2014
2015
2016
2017
Sales/Revenue
108.00
868.00
359.00
-
Cost of Goods Sold (COGS) incl. D&A
18,463.00
32,368.00
16,901.00
681.00
Gross Income
18,355.00
31,500.00
16,542.00
681.00
SG&A Expense
-
-
-
4,736.00
EBIT
18,355.00
31,500.00
16,542.00
5,417.00
Unusual Expense
-
-
107,622.00
-
Non Operating Income/Expense
711.00
262.00
1,760.00
272.00
Pretax Income
17,428.00
31,237.00
125,922.00
5,689.00
Consolidated Net Income
17,428.00
31,237.00
125,922.00
5,689.00
Net Income
17,428.00
31,237.00
125,922.00
5,689.00
Net Income After Extraordinaries
17,428.00
31,237.00
125,922.00
5,689.00
Net Income Available to Common
17,428.00
31,237.00
125,922.00
5,689.00
EPS (Basic)
2.04
2.41
9.10
0.41
Basic Shares Outstanding
8,534.30
12,985.90
13,830.00
13,830.00
EPS (Diluted)
1.88
2.27
9.10
0.41
Diluted Shares Outstanding
9,283.80
13,778.90
13,830.00
13,830.00
EBITDA
18,340.00
30,421.00
15,469.00
4,736.00
Non-Operating Interest Income
216.00
1.00
2.00
-

About Nicoccino Holding AB

View Profile
Address
Lahällsvägen 48
Täby AB 183 30
Sweden
Employees -
Website http://www.nicoccino.se
Updated 09/14/2018
Nicoccino Holding AB engages in the development, administration, and marketing of alternative nicotine product free from tobacco. Its Nicotine Replacement Therapy, delivers a potent nicotine effect without the side effects of smoking. The company was founded by Fredrik Hübinette on September 11, 2013 and is headquartered in Taby, Sweden.